---
title: "Introduction to htaBIM"
author: "Shubhram Pandey: Heorlytics Ltd"
date: "`r Sys.Date()`"
output: rmarkdown::html_vignette
vignette: >
  %\VignetteIndexEntry{Introduction to htaBIM}
  %\VignetteEngine{knitr::rmarkdown}
  %\VignetteEncoding{UTF-8}
---

```{r setup, include = FALSE}
knitr::opts_chunk$set(
  collapse = TRUE,
  comment  = "#>",
  fig.width  = 7,
  fig.height = 4.5
)
library(htaBIM)
```

## Overview

`htaBIM` provides a structured, reproducible framework for **budget impact
modelling (BIM)** in health technology assessment (HTA), following the ISPOR
Task Force guidelines (Sullivan et al., 2014; Mauskopf et al., 2007).

A budget impact model answers: *"If this new treatment is reimbursed, what is
the financial impact on the payer's budget over the next 1–5 years?"*

## Workflow

```
bim_population() -> bim_market_share() -> bim_costs() -> bim_model() -> outputs
```

## Step 1: Eligible population

The epidemiology funnel estimates the number of patients eligible for treatment
each year from a reference population size and cascade rates.

```{r population}
pop <- bim_population(
  indication     = "Disease X",
  country        = "custom",
  years          = 1:5,
  prevalence     = 0.003,
  n_total_pop    = 42e6,
  diagnosed_rate = 0.60,
  treated_rate   = 0.45,
  eligible_rate  = 0.30,
  growth_rate    = 0.005,
  data_source    = "Illustrative values only"
)
summary(pop)
```

## Step 2: Market shares

Define the mix of treatments in the current world (without new drug) and the
new world (with new drug), plus any scenario variants.

```{r market-share}
ms <- bim_market_share(
  population     = pop,
  treatments     = c("Drug C (SoC)", "Drug B", "Drug A (new)"),
  new_drug       = "Drug A (new)",
  shares_current = c("Drug C (SoC)" = 0.75, "Drug B" = 0.25, "Drug A (new)" = 0.00),
  shares_new     = c("Drug C (SoC)" = 0.60, "Drug B" = 0.20, "Drug A (new)" = 0.20),
  dynamics       = "linear",
  uptake_params  = list(ramp_years = 3),
  scenarios = list(
    conservative = c("Drug C (SoC)" = 0.68, "Drug B" = 0.22, "Drug A (new)" = 0.10),
    optimistic   = c("Drug C (SoC)" = 0.50, "Drug B" = 0.18, "Drug A (new)" = 0.32)
  )
)
print(ms)
```

## Step 3: Costs

Per-patient annual costs are built by treatment and cost category (drug, admin,
monitoring, adverse events, other). Adverse event costs can be computed from
an event-rate table.

```{r costs}
ae_tab <- data.frame(
  ae_name   = c("Injection site reaction", "Fatigue"),
  rate      = c(0.07, 0.12),
  unit_cost = c(180, 95)
)
ae_new <- bim_costs_ae("Drug A (new)", ae_tab)

costs <- bim_costs(
  treatments       = c("Drug C (SoC)", "Drug B", "Drug A (new)"),
  currency         = "GBP",
  price_year       = 2025L,
  drug_costs       = c("Drug C (SoC)" = 220,   "Drug B" = 22400, "Drug A (new)" = 28800),
  admin_costs      = c("Drug C (SoC)" = 0,     "Drug B" = 0,     "Drug A (new)" = 480),
  monitoring_costs = c("Drug C (SoC)" = 650,   "Drug B" = 1550,  "Drug A (new)" = 1950),
  ae_costs         = c("Drug C (SoC)" = 80,    "Drug B" = 210,   "Drug A (new)" = as.numeric(ae_new))
)
print(costs)
```

## Step 4: Assemble model

```{r model}
model <- bim_model(
  population    = pop,
  market_share  = ms,
  costs         = costs,
  payer         = bim_payer_nhs(),
  discount_rate = 0,
  label         = "Disease X -- Drug A BIM, NHS England"
)
summary(model)
```

## Step 5: Plots

```{r plot-line, fig.cap = "Annual budget impact by scenario"}
bim_plot_line(model, scenario = c("base", "conservative", "optimistic"))
```

```{r plot-shares, fig.cap = "Market share evolution"}
bim_plot_shares(model)
```

## Sensitivity analysis

### Deterministic (one-way) sensitivity analysis

```{r sensitivity}
sens <- bim_sensitivity_spec(
  prevalence_range           = c(0.0015, 0.005),
  eligible_rate_range        = c(0.20, 0.45),
  drug_cost_multiplier_range = c(0.85, 1.15)
)
dsa <- bim_run_dsa(model, sens, year = 5L)
```

```{r tornado, fig.cap = "DSA tornado diagram (Year 5)"}
bim_plot_tornado(dsa, currency = "GBP")
```

### Probabilistic sensitivity analysis (PSA)

PSA samples all uncertain parameters simultaneously from statistical
distributions (Beta for rates, LogNormal for costs) to produce a distribution
of budget impact outcomes.

```{r psa}
set.seed(42)
psa <- bim_run_psa(
  model,
  n_sim            = 200L,
  prevalence_se    = 0.0005,
  eligible_rate_se = 0.05,
  cost_cv          = 0.10,
  year             = 5L
)
print(psa)
```

```{r psa-plot, fig.cap = "PSA distribution of Year 5 budget impact"}
bim_plot_psa(psa)
```

## Scenario comparison table

`bim_scenario_table()` produces a side-by-side summary across all scenarios,
useful for dossier submissions.

```{r scenario-table}
st <- bim_scenario_table(model)
knitr::kable(st, caption = "Scenario comparison — budget impact summary")
```

## Cost breakdown

`bim_cost_breakdown()` decomposes the per-patient annual cost by component
for each treatment, aiding transparency.

```{r cost-breakdown}
cb <- bim_cost_breakdown(model)
knitr::kable(cb, caption = "Per-patient annual cost by component and treatment")
```

## Results table

```{r table}
tab <- bim_table(model, format = "annual", scenario = "base")
knitr::kable(tab, caption = "Annual budget impact -- base case")
```

## Built-in example data

```{r example}
data("bim_example")
pop2   <- do.call(bim_population,   bim_example$population_params)
ms2    <- do.call(bim_market_share,
                  c(list(population = pop2), bim_example$market_share_params))
costs2 <- do.call(bim_costs, bim_example$cost_params)
model2 <- bim_model(pop2, ms2, costs2)
summary(model2)
```

## Interactive app

An interactive Shiny dashboard is bundled with the package:

```r
htaBIM::launch_shiny()
```

A live demo is available at the link in the
[htaBIM pkgdown site](https://heorlytics.github.io/htaBIM/articles/shiny-app.html).

## References

Sullivan SD et al. (2014). Value in Health 17(1):5–14.
doi:10.1016/j.jval.2013.08.2291

Mauskopf JA et al. (2007). Value in Health 10(5):336–347.
doi:10.1111/j.1524-4733.2007.00187.x
